Italia markets closed

DBV Technologies S.A. (0QAJ.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
4,73470,0000 (0,00%)
Alla chiusura: 05:19PM GMT

DBV Technologies S.A.

177-181 Avenue Pierre Brossolette
Montrouge 92120
France
33 1 55 42 78 78
https://www.dbv-technologies.com

Settore/i
Settore
Impiegati a tempo pieno104

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Daniel TasséCEO & Director1,12MN/D1960
Dr. Pharis MohideenChief Medical Officer669,44kN/D1965
Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A.CFO & Principal Accounting OfficerN/DN/D1969
Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C.Chief Operations OfficerN/DN/DN/D
Ms. Michele F. RobertsonChief Legal OfficerN/DN/DN/D
Ms. Caroline DaniereChief Human Resources Officer & Chief of StaffN/DN/D1975
Dr. Wence AgbotounouChief Clinical Trial Officer & Senior VPN/DN/DN/D
Mr. Edward P. Jordan M.B.A.Senior Vice President of Commercial Operations North AmericaN/DN/D1968
Alan KerrSenior VP & Head of Global Regulatory AffairsN/DN/DN/D
Mr. Pascal WotlingChief External Manufacturing & Supply Chain OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Governance aziendale

L'ISS Governance QualityScore di DBV Technologies S.A. al 1 marzo 2024 è 10. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 9; diritti degli azionisti: 1; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.